Guest Opinion: Dems must educate ‘low-information voters’Struggling Syracuse looks to climb back above .500 when it hosts Albany on Tuesday night. The Orange (4-4) are coming off a conference loss to Notre Dame where they failed to make a 3-pointer in a game for the first time in more than 10 years, going 0-for-9 from behind the arc. They will be without leading scorer J.J. Starling, who broke his hand in practice last Monday. Orange coach Adrian Autry said there was "no timetable" for Starling's return after the loss to the Fighting Irish and lamented his team's struggles with turnovers and free-throw shooting in the defeat. "Too many blown opportunities," Autry said. "We're not shooting the ball well. We have to adjust and go game by game now. Our front court has been pretty secure, but we have to keep working and getting better." Starling was averaging a team-high 19.8 points before his injury. The Orange may need to lean more on freshman Donnie Freeman, who has been a standout for Syracuse this season. He's averaging 12.8 points and 8.8 rebounds and already has four double-doubles. He was co-ACC Rookie of the Week last week. Defensively, the Orange have struggled. They rank No. 329 in scoring defense, giving up 79.4 points per game. Albany is scoring 77.2 ppg so far this season. The Great Danes (6-4) were downed by Boston University 80-74 in overtime on Saturday. They started the season 5-1 but have lost three of their last four. Senior guard Byron Joshua, a transfer from Alcorn State, is the Great Danes' leading scorer at 13.6 ppg. Amar'e Marshall was an All-America East Conference pick last season after averaging 16.7 points, but his field goal shooting has dropped from 43.4 percent last season to 34.5 percent this season. He is scoring 11.7 ppg. "I think we're learning how to compete at the right level," Albany coach Dwyane Killings said after a loss to Georgetown on Nov. 30. "I think the one thing that troubles us a lot is that our identity and our energy comes when the ball goes in the basket. When it doesn't, I don't think we have the grit that we need right now." Albany has been one of the best teams in the country in terms of steals. The Great Danes average 10.2 steals per game, which is tied for No. 12 in the nation. Syracuse is 8-0 against Albany all-time with the teams last meeting in 2011. Syracuse is 4-0 at home and 4-0 against non-power-conference opponents. --Field Level MediaNone
NoneLOUISVILLE, Ky. (AP) — Louisville has approved a five-year contract extension through June 2030 for athletic director Josh Heird, whose 2 1/2-year tenure has included the hirings of two men’s basketball coaches and football coach Jeff Brohm. The university’s Board of Trustees on Thursday authorized President Kim Schatzel to execute the deal, three days after the University of Louisville Athletic Association board approved the agreement. Heird was named interim AD in December 2021 before being elevated to the full-time job the following June. Schatzel said in a release that the extension signals the school’s faith in Heird and added, “He is the right person and right leader” to take the athletic program forward to a bright future. Several significant personnel moves marked Heird’s initial tenure. He fired basketball coach Chris Mack in January 2022 and subsequently hired former Cardinals player Kenny Payne two months later. Heird fired Payne last March after two historically bad seasons and replaced him with Pat Kelsey on March 28. Heird also hired ex-Louisville quarterback and assistant Brohm in December 2022. The Cardinals won 10 games to reach the ACC championship game for the first time last season and are headed for a second consecutive postseason under the Louisville native with a berth in the Sun Bowl on Dec. 31 in El Paso, Texas. Heird has also extended contracts for women’s basketball coach Jeff Walz, volleyball coach Dani Busboom-Kelly and baseball coach Dan McDonnell. The AD’s other achievements include a $41 million naming rights deal for the Cardinal Stadium football field along with a $4 million club renovation. He also secured a $1 million donation to enhance Louisville's Jim Patterson Stadium baseball field. Heird also serves on the NCAA women’s basketball selection committee. AP sports: and
However, some state workers failed to return to their jobs and a United Nations official said the country’s public sector had come “to a complete and abrupt halt”. Meanwhile, streams of refugees crossed back into Syria from neighbouring countries, hoping for a more peaceful future and looking for relatives who disappeared during Mr Assad’s brutal rule. There were already signs of the difficulties ahead for the rebel alliance now in control of much of the country. The alliance is led by a former senior al-Qaida militant, who severed ties with the extremist group years ago and has promised representative government and religious tolerance. The rebel command said they would not tell women how to dress. “It is strictly forbidden to interfere with women’s dress or impose any request related to their clothing or appearance, including requests for modesty,” the command said in a statement on social media. Nearly two days after rebels entered the capital, some key government services had shut down after state workers ignored calls to go back to their jobs, the UN official said, causing issues at airports and borders and slowing the flow of humanitarian aid. Rebel leader Ahmad al-Sharaa, who was known by his nom de guerre Abu Mohammed al-Golani, also met with Prime Minister Mohammad Ghazi Jalali for the first time. Mr Jalali stayed in Syria when Mr Assad fled and has sought to project normalcy since. “We are working so that the transitional period is quick and smooth,” he told Sky News Arabia TV on Monday, saying the security situation had already improved from the day before. At the court of Justice in Damascus, which was stormed by the rebels to free detainees, Judge Khitam Haddad, an aide to the justice minister in the outgoing government, said that judges were ready to resume work quickly. “We want to give everyone their rights,” Mr Haddad said outside the courthouse. “We want to build a new Syria and to keep the work, but with new methods.” But a UN official said some government services had been paralysed as worried state employees stayed at home. The public sector “has just come to a complete and abrupt halt,” said Adam Abdelmoula, UN resident and humanitarian co-ordinator for Syria, noting, for example, that an aid flight carrying urgently needed medical supplies had been put on hold after aviation employees abandoned their jobs. “This is a country that has had one government for 53 years and then suddenly all of those who have been demonised by the public media are now in charge in the nation’s capital,” Mr Abdelmoula told The Associated Press. “I think it will take a couple of days and a lot of assurance on the part of the armed groups for these people to return to work again.” In a video shared on a rebel messaging channel, Mr al-Sharaa said: “You will see there are skills” among the rebels. The Kremlin said Russia has granted political asylum to Mr Assad, a decision made by President Vladimir Putin. Kremlin spokesperson Dmitry Peskov declined to comment on Mr Assad’s specific whereabouts and said Mr Putin did not plan to meet with him. Damascus was quiet Monday, with life slowly returning to normal, though most shops and public institutions were closed. In public squares, some people were still celebrating. Civilian traffic resumed, but there was no public transport. Long lines formed in front of bakeries and other food stores. There was little sign of any security presence though in some areas, small groups of armed men were stationed in the streets.NoneJada Williams' goal was to 'play for her team for 5 minutes' after sprained ankle against GCU
Toyota to invest $922 million to build a new paint facility at its Kentucky complex
Green Courte Partners Acquires Active-Adult Community Located in Atlanta, Georgia, MSAWabash Announces Quarterly Dividend
NoneWhite House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaign
Feds suspend ACA marketplace access to companies accused of falsely promising ‘cash cards’
None
Eat, pay, respect
IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNITM assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number instability (CNI) is a scientifically well-known hallmark of cancer. DetermaCNITM is a patented approach to measuring CNI for the diagnosis and monitoring of cancer. Nearly 300,000 patients in the U.S. each year face primary brain tumors or brain metastasis 1 . The current standard of care for the confirmation and classification of brain tumors often involves high-risk, highly invasive biopsy of brain tissue. Thus, a liquid biopsy method for diagnosing brain tumors could offer significant benefits over currently available methods, representing a potential $300 million U.S. market opportunity. Among the study authors were Oncocyte Chief Science Officer Ekke Schuetz and Senior R&D Director Julia Beck. "This was a proof of principle study to assess whether copy number instability could be measured in the cerebrospinal fluid of patients with brain cancer. The findings suggest that a significant number of the nearly 300,000 patients diagnosed with brain tumors every year in the U.S. could benefit from DetermaCNI,” Dr. Schuetz said. "We congratulate the research team in Frankfurt on the publication of this study in an area of high unmet need.” As noted in the paper, the gold standard for precise diagnostic classification of brain tumors requires a biopsy, with risks including limited sensitivity and failing to measure the diverse potential regions of the tumor. SCNAs were observed in the cerebrospinal fluid of ten out of the 12 patients with confirmed central nervous system cancers. SCNAs were not observed in any of the 11 patients with benign or unclear central nervous system lesions. The detection of SCNAs is highly specific for tumor-derived cell-free DNA (cfDNA). Overall, this new study demonstrates DetermaCNI's potential for providing a molecularly informed diagnosis of central nervous system cancers, mapping tumor heterogeneity, tracking tumor evolution, and surveilling tumor patients through a liquid biopsy of cerebrospinal fluid. Oncocyte believes this study validates the future clinical potential for DetermaCNI, as well as the direction of the company's research and development pipeline, which is designed to drive sustained rapid growth over the next decade. Oncocyte's mission is to democratize access to molecular diagnostic testing to improve patient outcomes. The company is investing in developing products to serve the separate verticals of organ transplant testing and oncology. Oncocyte is presently commercializing its transplant product line, which includes the VitaGraftTM and GraftAssureTM tests. It expects to commercialize its oncology assays over the next two years. _______________ 1 "Brain Metastases.” MD Anderson Cancer Center , www.mdanderson.org/cancer-types/brain-metastases.html. And "Brain Tumor Facts.” National Brain Tumor Society , 20 Feb. 2024, braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/. About Oncocyte Oncocyte is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraftTM is a clinical blood-based dd-cfDNA solid organ transplantation monitoring test. GraftAssureTM is a research use only (RUO) blood-based solid dd-cfDNA organ transplantation monitoring test kit for decentralized use. DetermaIOTM is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNITM is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/ . For more information about our products, please visit the following web pages: VitaGraft KidneyTM - https://oncocyte.com/vitagraft-kidney/ VitaGraft Liver TM - https://oncocyte.com/vitagraft-liver/ GraftAssureTM - https://oncocyte.com/graftassure/ DetermaIOTM - https://oncocyte.com/determa-io/ DetermaCNITM - https://oncocyte.com/determa-cni/ VitaGraftTM, GraftAssureTM, DetermaIOTM, and DetermaCNITM are trademarks of Oncocyte Corporation. CONTACT: Jeff Ramson PCG Advisory (646) 863-6893 [email protected] Forward-Looking Statements Any statements that are not historical fact (including, but not limited to statements that contain words such as "will,” "believes,” "plans,” "anticipates,” "expects,” "estimates,” "may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the belief that the new study validates the future clinical potential for DetermaCNI, as well as the direction of the company's research and development pipeline, the expectation that Oncocyte will commercialize its oncology assays over the next two years, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors” and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Cartel leader's son-in-law faked death to enable 'life of luxury' in Riverside, feds say
Jobs at risk in US advertising mega-merger: Omnicom and Interpublic to join forces in £10bn deal By CALUM MUIRHEAD Updated: 17:01 EST, 9 December 2024 e-mail View comments WPP’S status as the world’s largest advertising firm is under threat after two US rivals agreed a multi-billion-pound mega-merger. New York-based Omnicom and Interpublic, the second and fourth largest ad agencies, have struck a £10billion deal to join forces in a move that will de-throne FTSE 100 member WPP. The tie-up is likely to spark fears of job losses in the UK as both entities employ thousands of people across their various ad agencies and PR firms across Britain, and are planning to save £585million in costs through the merger. Globally, Omnicom has over 75,000 staff while Interpublic employs more than 57,000. Under the terms of the deal, Interpublic shareholders will receive 0.344 Omnicom shares for each share they hold in the business, giving them control of 39.4 per cent of the enlarged group. Tie-up: Omnicom, led by CEO John Wren (left) and Interpublic, led by CEO Maurice Levy (right), the second and fourth largest ad agencies, have struck a £10bn deal to join forces Omnicom chief executive John Wren said: ‘Now is the perfect time to bring together our technologies, capabilities, talent and geographic footprints to bring clients superior, data-driven outcomes.’ The merger is expected to attract intense scrutiny from competition regulators given the firm’s potential dominance over the sector. If it is completed, it will mean WPP will be overtaken in terms of advertising sales for the first time in 16 years. RELATED ARTICLES Previous 1 Next Kill the Royal Mail deal: Don't sell our postal service on... Nvidia sees value drop £80bn as Chinese regulators probe... Share this article Share HOW THIS IS MONEY CAN HELP How to choose the best (and cheapest) stocks and shares Isa and the right DIY investing account The London-based firm will be dwarfed by its combined rivals in terms of sales and market capitalisation, with Omnicom valued at £15.8billion while Interpublic is worth £8.5billion compared to WPP’s £9.4billion. Combined, the two US firms reported revenues of around £20billion last year compared to £14.8billion for WPP. The deal would also see the world’s ‘Big Four’ ad agencies reduced to three, with WPP competing with the newly merged firm, as well as French giant Publicis Group, which owns ad agency Saatchi & Saatchi. WPP’s shares have struggled following the departure of its founder and long-serving boss Sir Martin Sorrell in 2018. But shares rose 2.8 per cent, or 24p, to 891.6p yesterday as investors considered whether the merger could provide opportunities for the group. DIY INVESTING PLATFORMS AJ Bell AJ Bell Easy investing and ready-made portfolios Learn More Learn More Hargreaves Lansdown Hargreaves Lansdown Free fund dealing and investment ideas Learn More Learn More interactive investor interactive investor Flat-fee investing from £4.99 per month Learn More Learn More Saxo Saxo Get £200 back in trading fees Learn More Learn More Trading 212 Trading 212 Free dealing and no account fee Learn More Learn More Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence. Compare the best investing account for you Share or comment on this article: Jobs at risk in US advertising mega-merger: Omnicom and Interpublic to join forces in £10bn deal e-mail Add comment Some links in this article may be affiliate links. If you click on them we may earn a small commission. That helps us fund This Is Money, and keep it free to use. We do not write articles to promote products. We do not allow any commercial relationship to affect our editorial independence. More top stories
Celebrity travel files: This is what actress Chen Yixin packs for a three-night beach escape